Clinical trials: Sirolimus
Coronary Artery Disease
The Dual Antiplatelet Therapy Study (DAPT Study)
The DAPT Study is a double blind randomized controlled trial intended to determine the appropriate duration for dual antiplatelet therapy (the combination of aspirin and a second anti-clotting medication) as well as the safety…
- Trial name
- NCT00977938
- Testing
- Clopidogrel & Aspirin, Prasugrel & Aspirin
- Where
- 256 sites in United States, Australia and 8 more
- Volunteers
- 25,682 people
- Sponsor
- Baim Institute for Clinical Research
Type 1 Diabetes, Hypoglycemia
Islet Allotransplantation With Steroid Free Immunosuppression
The restoration of endogenous insulin secretion carries significant hopes for shifting the paradigm of life long exogenous insulin therapy in selected groups of patients with type 1 diabetes(T1D).
- Conditions
- Type 1 Diabetes, Hypoglycemia, Metabolic Diseases
- Trial name
- NCT00446264
- Testing
- islet transplantation, daclizumab - sirolimus - tacrolimus
- Where
- France
- Volunteers
- 14 people
- Sponsor
- University Hospital, Lille
Lymphangioleiomyomatosis, Tuberous Sclerosis Complex
Feasibility of [11C]Acetate-PET in LAM and TSC
This study aims to assess [11C]acetate positron emission tomography (PET)/computed tomography (CT) as a biomarker for renal angiomyolipomas and pulmonary lymphangioleiomyomatosis (LAM) and an early biomarker of response to…
- Trial name
- NCT05467397
- Testing
- [11C]acetate
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Brigham and Women's Hospital
Metastatic Breast Cancer
A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi
This study was a multicenter, randomized, double-blind, placebo-controlled Phase III study to determine the efficacy and safety of treatment with Buparlisib plus Fulvestrant vs.
- Trial name
- BELLE-3 (NCT01633060)
- Testing
- Fulvestrant, BKM120
- Where
- 197 sites in United States, Argentina and 20 more
- Volunteers
- 432 people
- Sponsor
- Novartis Pharmaceuticals
Epilepsy, Tuberous Sclerosis Complex
A Pilot Study To Evaluate The Effects of Everolimus on Brain mTOR Activity and Cortical Hyperexcitability in TSC and FCD
The purpose of this study is to measure if the drug called Everolimus effects mTOR signaling (an electrical activity signal in the brain) in patients with Tuberous Sclerosis Complex (TSC) and Focal Cortical Dysplasia (FCD) with…
- Conditions
- Epilepsy, Tuberous Sclerosis Complex, Focal Cortical Dysplasia
- Trial name
- NCT02451696
- Testing
- Everolimus
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- NYU Langone Health
Renal Transplant Rejection, Immunosuppression
Cytokines Evaluation in Early Calcineurin Inhibitors Withdrawn on Renal Transplant
Currently, acute kidney injury is diagnosed by increased serum creatinine. However, creatinine is not a reliable marker for acute changes in renal function.
- Trial name
- NCT01239472
- Testing
- Everolimus
- Where
- Brazil
- Volunteers
- 30 people
- Sponsor
- Andre Barreto Pereira
Brain Tumor, Glioblastoma
Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas
The goal of Phase 1 of this clinical research study is to find the highest tolerable dose and best schedule of the combination of everolimus and sorafenib that can be given to patients with malignant glioma.
- Conditions
- Brain Tumor, Glioblastoma, Anaplastic Glioma
- Trial name
- NCT01434602
- Testing
- everolimus, sorafenib
- Where
- United States
- Volunteers
- 86 people
- Sponsor
- National Cancer Institute (NCI)
Kaposiform Hemangioendothelioma (KHE), Kasabach-Merritt Syndrome
A Study to Compare Vincristine to Sirolimus for Treatment of High Risk Vascular Tumors
In this research study we want to learn more about which treatment works better for patients diagnosed with a vascular tumor called Kaposiform Hemangioendothelioma (KHE) or other high risk vascular tumors such as Tufted Angioma…
- Conditions
- Kaposiform Hemangioendothelioma (KHE), Kasabach-Merritt Syndrome, Tufted Angioma
- Trial name
- NCT02110069
- Testing
- Vincristine, Sirolimus
- Where
- 7 sites in United States
- Volunteers
- 4 people
- Sponsor
- Boston Children's Hospital
PIK3CA-Related Overgrowth Spectrum (PROS), Growth Disorder
Study of Sirolimus Therapy for Segmental Overgrowth Caused by Somatic PI3K Activation
Background: PIK3CA-related overgrowth spectrum (PROS) is caused by changes in the PIK3CA gene. This gene makes a protein that communicates with other proteins in the body to cause cells to grow.
- Conditions
- PIK3CA-Related Overgrowth Spectrum (PROS), Growth Disorder, Genetics
- Trial name
- NCT02428296
- Testing
- Sirolimus
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- National Human Genome Research Institute (NHGRI)
Prostate Cancer
RAD001 and Bicalutamide for Androgen Independent Prostate Cancer
In the treatment of castration-resistant prostate cancer (CRPC), therapies will long response durations remain elusive as a result of the inherent ability of prostate cancer cells to develop iterative resistance.
- Trial name
- NCT00630344
- Testing
- RAD001, Bicalutamide
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- Dana-Farber Cancer Institute
Recurrent Melanoma, Stage IV Melanoma
Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery
This randomized phase II trial is studying how well giving sorafenib together with either temsirolimus or tipifarnib works in treating patients with stage IV melanoma that cannot be removed by surgery.
- Trial name
- NCT00281957
- Testing
- sorafenib tosylate, tipifarnib, temsirolimus
- Where
- 173 sites in United States
- Volunteers
- 109 people
- Sponsor
- National Cancer Institute (NCI)
Adult Synovial Sarcoma, Recurrent Adult Soft Tissue Sarcoma
Everolimus in Combination With Imatinib Mesylate in Treating Patients With Locally Advanced, Locally Recurrent, or Metastatic Soft Tissue Sarcoma
This phase I/II clinical trial is studying the side effects and best dose of everolimus when given with imatinib mesylate and to see how well they work in treating patients with locally advanced, locally recurrent or metastatic…
- Conditions
- Adult Synovial Sarcoma, Recurrent Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma
- Trial name
- NCT01281865
- Testing
- diagnostic laboratory biomarker analysis, everolimus, imatinib mesylate
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- National Cancer Institute (NCI)
Liver Transplantation
Efficacy of Everolimus in Combination With Tacrolimus in Liver Transplant Recipients
This trial evaluated the efficacy and safety of Everolimus in combination with tacrolimus versus a standard immunosuppressive regimen concerning kidney function in liver transplant recipients.
- Trial name
- HEPHAISTOS (NCT01551212)
- Testing
- Everolimus, Tacrolimus, Corticosteroids
- Where
- 15 sites in Germany
- Volunteers
- 339 people
- Sponsor
- Novartis Pharmaceuticals
Complication of Renal Dialysis, End Stage Renal Disease
A Study Testing the Use of a Perivascular Sirolimus Formulation (Sirogen) in ESRD Patients Undergoing AV Fistula Surgery
The primary study objective is to evaluate the benefit of the Sirolimus eluting Collagen implant (SeCI; Sirogen), a single dose prophylactic treatment delivered intraoperatively at the time of surgical creation of an…
- Conditions
- Complication of Renal Dialysis, End Stage Renal Disease, End Stage Kidney Disease, ESRD
- Trial name
- ACCESS2 (NCT05425056)
- Testing
- Sirolimus
- Where
- 22 sites in United States, United Kingdom
- Volunteers
- 136 people
- Sponsor
- Vascular Therapies, Inc.
Estrogen Receptor Negative, HER2/Neu Negative
Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer
This phase I/IB trial studies the side effects and best dose of eribulin mesylate and everolimus in treating patients with breast cancer that does not have estrogen receptors, progesterone receptors, or large amounts of human…
- Conditions
- Estrogen Receptor Negative, HER2/Neu Negative, Progesterone Receptor-negative, Stage IV Breast Cancer
- Trial name
- NCT02120469
- Testing
- everolimus, eribulin mesylate, pharmacological study
- Where
- 3 sites in United States
- Volunteers
- 27 people
- Sponsor
- City of Hope Medical Center
Age-Related Macular Degeneration, Geographic Atrophy
Sirolimus for Advanced Age-Related Macular Degeneration
This study will determine whether a drug called sirolimus is safe to give to people with geographic atrophy (GA) and if it can help preserve vision in patients.
- Trial name
- SIRGA2 (NCT01445548)
- Testing
- Sirolimus
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- National Eye Institute (NEI)
Inherited Immune Deficiencies
Donor Stem Cell Transplantation for Congenital Immunodeficiencies
This study uses transplantation to treat patients with problems in their immune system. The immune system cells come from the bone marrow where they grow from special cells called stem cells.
- Trial name
- NCT00426517
- Testing
- Campath 1H, Busulfan, Horse Anti-human Thymocyte Globulin (h-ATG)
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Neoplasms
BI 836845 in Estrogen Receptor Positive Metastatic Breast Cancer
Phase Ib / II study to determine the Maximum Tolerated Dose and Recommended Phase II Dose, and to evaluate the safety and antitumour activity, of BI 836845 and everolimus in combination with exemestane in women with HR+/HER2…
- Trial name
- NCT02123823
- Testing
- Everolimus, Exemestane, BI 836845
- Where
- 38 sites in Austria, Belgium and 8 more
- Volunteers
- 164 people
- Sponsor
- Boehringer Ingelheim
Intracranial Meningioma
Trial of the Combination of Bevacizumab and Everolimus in Patients With Refractory, Progressive Intracranial Meningioma
In this multicenter, Phase II trial, the investigators plan to evaluate the activity of the combination of bevacizumab and everolimus in patients with recurrent, progressive meningioma following maximal treatment with surgical…
- Trial name
- NCT00972335
- Testing
- Everolimus, Bevacizumab
- Where
- 7 sites in United States
- Volunteers
- 18 people
- Sponsor
- SCRI Development Innovations, LLC
Advanced Cancers
Phosphatidylinositol 3 Kinase and Mammalian Target of Rapamycin (PI3K-mTOR) in Advanced Cancer Patients
The goal of this clinical research study is to learn if temsirolimus can help to control advanced cancer in patients who also have a PI3K mutation and/or PTEN loss. The safety of this drug will also be tested.
- Trial name
- NCT00877773
- Testing
- Temsirolimus
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- M.D. Anderson Cancer Center